SCHEMBL7609852

SCHEMBL7609852

O=C1Nc2ncccc2/C1=C/Nc1ccc(N2CCOCC2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 2/20 0.41
MAPT P10636 4/20 0.40
GAA P10253 2/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
APP P05067 1/20 0.40
SNCA P37840 1/20 0.40
CNR2 P34972 3/20 0.39
PDGFRB P09619 1/20 0.39
STAT3 P40763 1/20 0.39
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
KDM4E B2RXH2 1/20 0.38
KCNQ3 O43525 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609857 1.00 RAB9A (0.41) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7612677 0.85 RAB9A (0.42) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7612701 0.85 RAB9A (0.42) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7611753 0.84 FLT3 (0.46) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7611744 0.84 FLT3 (0.46) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7605917 0.84 MAPT (0.43) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7605913 0.84 MAPT (0.43) RAB9ANPC1SMN1; SMN2LMNACYP1A2
SCHEMBL7611470 0.84 DGAT1 (0.44) RAB9ANPC1CYP1A2CNR2
SCHEMBL7611481 0.84 DGAT1 (0.44) RAB9ANPC1CYP1A2CNR2
SCHEMBL7616464 0.81 HDAC3 (0.37) RAB9ANPC1SMN1; SMN2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX RAB9A 2426/4885NPC1 4728/4885SMN1; SMN2 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.